Presentations

Opthea To Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference August 17.

Webcast

Opthea To Present at H.C. Wainwright Annual Global Life Sciences Conference

Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at H.C. Wainwright Annual Global Life Sciences Conference May 23-25.

Webcast

Opthea To Present at Citi Biopharma Virtual Co-Panel day

Dr Megan Baldwin, the Company’s Chief Executive Officer, will present on the Citi Biopharma virtual Co-Panel day Ophthalmology Panel on May 18, 2022

Webcast

ARVO 2022 Annual Meeting

Opthea Presented Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy at ARVO 2022

Poster Presentation

ASX Small – Mid Cap Conference 2022

Opthea Presented at the ASX Small – Mid Cap Conference 2022

Presentation RecordingProactive Investor

Angiogenesis 2022 – Prof Cheung presentation of PCV data

OPT-302 Combination Therapy in Polypoidal Choroidal Vasculopathy.

 

Download PDF
Opthea Corporate Presentation August 2022

 

Download the Presentation Slides

MST Access Initiation of Coverage report: In its ‘Lines’ of Sight

Download the report

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call

Download the transcript

Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York
MST Access Initiation of Coverage report: In its ‘Lines’ of Sight

Download the report

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call

Download the transcript

Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York

Presentation